NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as NOVARTIS. It is marketed under 1 brand name, including SCEMBLIX. Available in 3 different strengths, such as EQ 20MG BASE, EQ 40MG BASE, EQ 100MG BASE, and administered through 1 route including TABLET;ORAL. The latest reported annual revenue is $104,972,035 in 2024.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"98906","ingredient":"ASCIMINIB HYDROCHLORIDE","trade_name":"SCEMBLIX","family_id":"defdd385a30a4b398af6","publication_number":"US8829195B2","cleaned_patent_number":"8829195","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2033-05-13","publication_date":"2014-09-09","legal_status":"Granted"} | US8829195B2 Molecular | 09 Sep, 2014 | Granted | 13 May, 2033 | |
| {"application_id":"119007","ingredient":"ASCIMINIB HYDROCHLORIDE","trade_name":"SCEMBLIX","family_id":"c5de30ad6fb948b6a192","publication_number":"US11407735B2","cleaned_patent_number":"11407735","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-05-14","publication_date":"2022-08-09","legal_status":"Granted"} | US11407735B2 Molecular | 09 Aug, 2022 | Granted | 14 May, 2040 | |
| {"application_id":"113346","ingredient":"ASCIMINIB HYDROCHLORIDE","trade_name":"SCEMBLIX","family_id":"c5de30ad6fb948b6a192","publication_number":"US20230089503A1","cleaned_patent_number":"12252478","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-05-14","publication_date":"2023-03-23","legal_status":"Pending"} | US12252478B2 Formulation | 23 Mar, 2023 | Pending | 14 May, 2040 | |
| {"application_id":"113345","ingredient":"ASCIMINIB HYDROCHLORIDE","trade_name":"SCEMBLIX","family_id":"c5de30ad6fb948b6a192","publication_number":"US20230074064A1","cleaned_patent_number":"12252479","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-05-17","publication_date":"2023-03-09","legal_status":"Granted"} | US12252479B2 | 09 Mar, 2023 | Granted | 17 May, 2040 |
Country wise drug prices over the years
Country wise drug revenue over the years
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Asciminib Hydrochloride
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.